DAPT Calculator
Estimate your DAPT Calculator with our free cardiovascular system calculator. See reference ranges, risk factors, and next-step guidance.
Reviewed for accuracy by Rahul Singh, Health & Wellness Specialist
Medical disclaimer: This calculator is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Results are general estimates and may not reflect your individual circumstances. Always consult a qualified healthcare professional before making decisions about your health.
DAPT Calculator
Calculator
Adjust values & calculateEnter your values below. Every result is computed in your browser — no data is sent to any server.
Formula: DAPT Score = Age points + Smoking + Diabetes + MI + Prior PCI + Stent size + Stent type + CHF + Vein graft
Worked example — DAPT Score: 4 (>=2, prolonged DAPT for 30 months is favored)
Formula
DAPT Score = Age points + Smoking + Diabetes + MI + Prior PCI + Stent size + Stent type + CHF + Vein graft
Age provides -2 (75+), -1 (65-74), or 0 (<65) points. Other factors add +1 or +2 points each. Total ranges from -2 to 10. Score of 2 or higher favors extended 30-month DAPT; below 2 favors standard 12-month duration.
Worked Examples
Example 1: Score Favoring Prolonged DAPT
Problem:A 58-year-old male smoker with diabetes who presented with MI, received a 2.5mm DES. No prior PCI, no CHF, no vein graft. Calculate DAPT score at 12 months.
Solution:Age <65: 0 points Cigarette smoking: +1 Diabetes: +1 MI at presentation: +1 Prior PCI/MI: 0 Stent diameter <3mm: +1 Paclitaxel stent: 0 CHF/LVEF <30%: 0 Vein graft: 0 Total DAPT Score = 4
Result:DAPT Score: 4 (>=2, prolonged DAPT for 30 months is favored)
Example 2: Score Favoring Standard Duration
Problem:A 76-year-old non-smoking, non-diabetic patient who had elective PCI with a 3.5mm DES for stable angina. No prior PCI, no CHF, no vein graft.
Solution:Age >=75: -2 points Cigarette smoking: 0 Diabetes: 0 MI at presentation: 0 (stable angina) Prior PCI/MI: 0 Stent diameter <3mm: 0 (3.5mm stent) Paclitaxel stent: 0 CHF/LVEF <30%: 0 Vein graft: 0 Total DAPT Score = -2
Result:DAPT Score: -2 (<2, standard 12-month DAPT duration is favored)
Frequently Asked Questions
What is the DAPT score and what does it determine?
The DAPT (Dual Antiplatelet Therapy) score is a clinical decision-support tool developed to help determine the optimal duration of dual antiplatelet therapy after coronary stent implantation. The score was derived from the landmark DAPT Study, which randomized over 11,000 patients who had tolerated 12 months of DAPT without events to either continued thienopyridine therapy or placebo for an additional 18 months. The score integrates nine clinical and procedural variables to produce a value ranging from -2 to 10. A score of 2 or higher identifies patients who derive greater ischemic benefit from prolonged DAPT (30 months) relative to the increased bleeding risk, while a score below 2 suggests the bleeding risk of extended therapy outweighs the ischemic benefit. The tool helps personalize treatment duration rather than applying a one-size-fits-all approach.
How is the DAPT score calculated and what are its components?
The DAPT score assigns points based on nine clinical and procedural factors assessed at the time of the decision about extending DAPT beyond 12 months. Age provides negative points: age 75 or older gets -2, age 65-74 gets -1, and age under 65 gets 0 points. Positive points are assigned for current cigarette smoking (+1), diabetes mellitus (+1), MI at presentation (+1), prior PCI or prior MI (+1), stent diameter less than 3 mm (+1), paclitaxel-eluting stent (+1), CHF or LVEF less than 30 percent (+2), and saphenous vein graft PCI (+2). The total score ranges from -2 to 10. The scoring reflects the balance between ischemic risk factors (which favor prolonged therapy) and bleeding risk factors (primarily age, which favors shorter therapy).
What is dual antiplatelet therapy and why is duration important?
Dual antiplatelet therapy consists of aspirin combined with a P2Y12 receptor inhibitor (clopidogrel, prasugrel, or ticagrelor) given after coronary stent placement or acute coronary syndrome. This combination is essential to prevent stent thrombosis, a potentially catastrophic complication where a blood clot forms inside the stent causing acute vessel occlusion and myocardial infarction. The duration of DAPT represents a critical balance: too short a duration risks stent thrombosis and recurrent ischemic events, while too long a duration increases bleeding complications without proportional ischemic benefit. Standard duration is typically 6 to 12 months after drug-eluting stent placement, but individual risk profiles may warrant shorter (1-3 months in high bleeding risk) or longer (beyond 12 months in high ischemic risk) durations.
When should the DAPT score be applied in clinical practice?
The DAPT score should be applied at or around the 12-month mark after coronary stent implantation to guide the decision about whether to continue or discontinue the P2Y12 inhibitor component of dual antiplatelet therapy. Critically, the score is only valid for patients who have completed 12 months of DAPT without experiencing a major bleeding event, myocardial infarction, or stroke during that period. Patients who have complications during the initial 12 months require individualized assessment rather than score-based guidance. The score is most applicable to patients who received drug-eluting stents, as bare-metal stents typically require only 1 month of DAPT. Additionally, the score was developed primarily for patients on clopidogrel and may not directly apply to those on prasugrel or ticagrelor, though the risk factor principles remain relevant.
Why does older age reduce the DAPT score rather than increase it?
Older age receives negative points in the DAPT score because aging significantly increases bleeding risk while having a more complex relationship with ischemic benefit. Elderly patients have age-related changes including increased vascular fragility, declining renal and hepatic function affecting drug metabolism, higher prevalence of anemia, increased fall risk, and greater use of concomitant medications that interact with antiplatelet agents. Analysis of the DAPT trial data showed that patients aged 75 and older had substantially higher rates of moderate to severe bleeding with prolonged DAPT without a proportional reduction in ischemic events. The net clinical benefit (ischemic events prevented minus bleeding events caused) was negative for extended DAPT in elderly patients. This finding aligns with the general principle in anticoagulation and antiplatelet medicine that bleeding risk escalates more steeply with age than ischemic risk reduction.
What are the risks of stent thrombosis if DAPT is stopped too early?
Stent thrombosis is among the most feared complications after coronary intervention, occurring when a blood clot forms within the stent and abruptly occludes the coronary artery. It presents as acute myocardial infarction with mortality rates of 20 to 45 percent per event. Stent thrombosis is classified by timing: acute (within 24 hours), subacute (1-30 days), late (30 days to 1 year), and very late (beyond 1 year). Premature discontinuation of DAPT is the strongest predictor of stent thrombosis, with risk increasing 90-fold in the first 30 days and remaining elevated for months. First-generation drug-eluting stents had higher rates of very late stent thrombosis (0.4-0.6 percent per year) compared to newer-generation stents (0.1-0.2 percent per year), which have thinner struts and more biocompatible polymers. The improved safety profile of contemporary stents has enabled consideration of shorter DAPT durations in selected low-risk patients.
How do newer P2Y12 inhibitors affect the DAPT duration decision?
Prasugrel and ticagrelor are more potent P2Y12 inhibitors than clopidogrel, providing faster onset, greater platelet inhibition, and more consistent pharmacological effect. The TRITON-TIMI 38 trial showed prasugrel reduced ischemic events by 19 percent compared to clopidogrel but increased major bleeding by 32 percent, with particular harm in patients over 75, those with prior stroke, and those weighing less than 60 kg. The PLATO trial demonstrated ticagrelor reduced cardiovascular death by 21 percent compared to clopidogrel with modestly increased non-CABG bleeding. When considering DAPT duration with these agents, their greater antiplatelet potency means both the ischemic protection and bleeding risk per unit time are amplified compared to clopidogrel. Some clinicians use the DAPT score as a framework but apply lower thresholds for extended duration or consider de-escalation strategies switching from potent agents to clopidogrel after an initial high-risk period.
What bleeding complications can occur with prolonged DAPT?
Prolonged dual antiplatelet therapy increases the risk of various bleeding complications through sustained inhibition of platelet aggregation. Gastrointestinal bleeding is the most common major bleeding site, occurring in approximately 1 to 2 percent of patients per year on DAPT, often from peptic ulcers, erosive gastritis, or lower GI sources. Intracranial hemorrhage, though rare at 0.1 to 0.3 percent annually, is the most devastating complication with high mortality and morbidity. Other bleeding manifestations include epistaxis, hematuria, bruising, and prolonged bleeding from minor wounds. The DAPT trial showed that extending therapy from 12 to 30 months increased GUSTO moderate or severe bleeding from 1.6 to 2.5 percent. Proton pump inhibitor co-prescription reduces GI bleeding risk significantly and is recommended for all patients on DAPT with risk factors including age over 65, concurrent anticoagulation, corticosteroid use, or prior GI bleeding.
How does the type of stent influence DAPT duration decisions?
Stent type significantly influences both the minimum required DAPT duration and the potential benefit of extended therapy. Bare-metal stents complete endothelialization within 4 to 6 weeks, requiring only 1 month of DAPT in most guidelines. First-generation drug-eluting stents (sirolimus and paclitaxel-eluting) had delayed endothelialization and higher rates of very late stent thrombosis, traditionally requiring 12 months of DAPT. Contemporary second and third-generation drug-eluting stents with thinner struts, biodegradable polymers, or polymer-free designs demonstrate faster healing and lower thrombosis rates, enabling consideration of shorter DAPT (3-6 months) in appropriate patients. The DAPT score includes paclitaxel-eluting stent as a positive predictor because this stent type was associated with higher late thrombosis rates. Bioresorbable vascular scaffolds, though now largely abandoned, initially required extended DAPT due to higher scaffold thrombosis rates.
What alternative strategies exist for patients who cannot tolerate prolonged DAPT?
Several strategies have been developed for patients who cannot tolerate prolonged DAPT due to bleeding risk, planned surgery, or intolerance. Short-term DAPT (1-3 months) followed by P2Y12 inhibitor monotherapy (dropping aspirin) has shown promise in trials like TWILIGHT and TICO, reducing bleeding by 40 to 50 percent without increasing ischemic events. De-escalation from potent P2Y12 inhibitors (prasugrel or ticagrelor) to clopidogrel after 1 to 3 months of the acute phase combines early potent inhibition with later reduced bleeding risk. Platelet function testing can identify patients with adequate platelet inhibition on lower-intensity regimens. For patients requiring non-cardiac surgery, guidelines provide specific recommendations for DAPT interruption timing based on stent type and surgical bleeding risk. Left atrial appendage closure can eliminate the need for long-term oral anticoagulation in AF patients on DAPT, reducing the triple therapy burden.
References
- Yeh RW, et al. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy. JAMA. 2016;315(16):1735-1749.
- Mauri L, et al. Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents (DAPT Study). N Engl J Med. 2014;371(23):2155-2166.
- Levine GN, et al. 2016 ACC/AHA Focused Update on Duration of DAPT. Circulation. 2016;134(10):e123-e155.
Reviewed for accuracy by Rahul Singh, Health & Wellness Specialist · Editorial policy
Related Calculators
🧮Addiction Calculator
Calculate addiction with inputs, formulas, and instant results.
🧮Alcohol Unit Calculator
Calculate alcohol unit with inputs, formulas, and instant results.
🧮AUDIT-C Calculator
Calculate audit ccalculator with inputs, formulas, and instant results.
🧮AUDIT Full Questionnaire Calculator
Calculate auditfull questionnaire with inputs, formulas, and instant results.
🧮AUDIT Score Calculator
Calculate audit score with inputs, formulas, and instant results.
🧮CAGE Questionnaire Calculator
Calculate cagequestionnaire with inputs, formulas, and instant results.
🧮Cigarette Calculator
Calculate cigarette with inputs, formulas, and instant results.
🧮DAST-10 Drug Abuse Screening Calculator
Calculate dast10drug abuse with inputs, formulas, and instant results.